Zanubrutinib and lenalidomide as maintenance treatment for diffuse large B-cell lymphoma
Tests two drugs as maintenance treatment in people with diffuse large B-cell lymphoma.
Plain-language title generated from the registry record
Registry title: Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
Where in China
- Navy General HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Navy General Hospital, Beijing
- Trial code
- NCT06503263
- Record updated
- 19 September 2024
- Original description
The goal of this phase 2 trial is to test the safety and efficacy of zanubrutinib and lenalidomide as maintenance therapy in patients with DLBCL.Read full original descriptionShow less
Zanubrutinib and Lenalidomide as Maintenance Therapy in Patients With Diffuse Large B-cell Lymphoma
The goal of this phase 2 trial is to test the safety and efficacy of zanubrutinib and lenalidomide as maintenance therapy in patients with DLBCL.
Inclusion: Pathologically confirmed Diffuse Large B Cell Lymphoma according World Health Organization (WHO) classification; Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF); Patient must understand and voluntarily sign an ICF prior to any study-specific assessments/procedures being conducted; Patient is willing and able to adhere to the study visit schedule and other protocol requirements; Patient has recieved complete remission and has completed planed courses of chemotherapy; Meet the following lab criteria: Absolute Neutrophil Count (ANC) ≥ 1,5 x 10\^9/L (≥ 1 x 10\^9/L if bone marrow (BM) involvement by lymphoma)；Platelet ≥ 75 x 10\^9/L (≥ 50 x 10\^9/L if BM involvement by lymphoma)； Hemoglobin ≥ 8 g/dL. Anticipated life expectancy at least 3 months.
Exclusion: Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment; Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy; Pregnant or lactating women.